On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Learn about the STYLE clinical trial study design, primary endpoint (the proportion of patients who achieved ScPGA response at week 16) and Important Safety Information.
Explore data on the ScPGA response through 32 weeks of treatment.
Learn about scalp itch and whole body itch data through 16 and 32 weeks of treatment.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations